Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Lumos Pharma
Actuate Therapeutics Inc.
Bristol-Myers Squibb
AstraZeneca
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
Genfleet Therapeutics (Shanghai) Inc.
Incyte Corporation
DEKA Biosciences